Rezera Inc. S-1/Aamended IPO prospectus

Executive Summary

Rezera develops oral anti-inflammatory drugs for cardiovascular and neurological patients; it has no approved products or revenue. Its priority is ruvonoflast for peripheral artery disease, moving toward a pivotal trial despite never having tested the drug in that patient population. Development spending is accelerating, with H1 2026 net loss reaching $(25.5)M. The unpriced IPO implies a $229M–$270M valuation and gives buyers 80.2% of outstanding shares: the investment case rests on turning encouraging inflammation biomarkers into meaningful clinical benefit.

Business Model and Growth Drivers

Rezera owns worldwide rights to its pipeline and intends to commercialize ruvonoflast itself in the U.S., initially through ≈50 specialist centers. Management estimates a ≈$5B peripheral artery disease market, but that depends on approval, pricing, reimbursement and adoption—not existing demand.

Ruvonoflast inhibits NLRP3, an upstream driver of inflammation. Its five completed human trials support biological activity, not proven benefit for walking, limb preservation or cardiovascular outcomes. In the 176-patient RESOLVE-1 trial, the primary weight-loss endpoint failed. A post-hoc subgroup selected for inflammation and adherence showed week-four reductions of 56%–63% in high-sensitivity C-reactive protein, an inflammation marker. Six-month safety showed no imbalance in adverse events or infections versus placebo. RESOLVE-2 also showed additional inflammation reduction alongside semaglutide, but no additional weight loss.

Management plans the ≈800-patient RELIEVE-PAD Phase 3 trial for H1 2027, measuring maximum walking distance after ≈12 months. Topline results are targeted for 2028 and a marketing application for early 2029; regulatory discussions do not guarantee that one trial will suffice. Trabzanoflast, designed to penetrate the brain, has completed Phase 1 and awaits proof-of-concept development.

The Offering

• Size and valuation: Rezera offers 16,666,667 primary shares at $11.00–$13.00; there are no secondary sales. Computed implied gross proceeds are $183M–$217M and market capitalization is $229M–$270M, based on 20,776,793 post-offering shares. Enumerated outstanding options and warrants bring the diluted count to 21,707,410 and valuation to $239M–$282M, before conditional IPO awards and unused reserves. Revenue and earnings multiples are not meaningful.
• Terms: The offering remains unpriced. Jefferies, TD Securities and Cantor Fitzgerald lead it; Nasdaq listing under RZRA is a closing condition. Underwriters have a 30-day option for 2,500,000 additional shares.
• Proceeds: Estimated net proceeds at the $12.00 midpoint are $181M, or $209M with the option fully exercised. The company receives the money for ruvonoflast development and general purposes. Combined resources are expected to fund Phase 3 topline results and operations through Q1 2029, but not regulatory approval or trabzanoflast Phase 2 topline results.
• GSK interest: Glaxo Group Limited has indicated a nonbinding purchase of up to $25.0M within the IPO. Meeting the contractual purchase threshold activates negotiation rights over specified ruvonoflast transactions and a change of control—not a licensing commitment.
• Dilution: Each $12.00 share would be backed by $9.52 of net tangible assets after the IPO, a $2.48 gap. Existing holders paid a weighted-average $53.81 per share, an unusual premium to the proposed price.
• Resale: Directors, executives and substantially all existing holders face 180-day lock-ups, subject to exceptions and waiver; afterward, up to 4,110,126 additional shares may become eligible for sale.

Key Financial Highlights

Figures in $M; losses and cash outflows are parenthesized.

• Spending drivers: H1 2026 ruvonoflast spending reached $13.9M vs $4.70M, explaining nearly all incremental R&D. FY2025 also lacked $4.00M of U.K. incentives that reduced FY2024 expense.
• Non-operating effects: H1 currency results swung from a $2.00M gain to a $(1.45)M loss as exchange rates changed intercompany funding balances; the prior period also included a $2.20M convertible-note valuation loss.
• Cash conversion: H1 operating-asset and liability movements offset $7.00M of losses, including clinical prepayments and accrued costs. Repaying a separate $6.40M recovery-related note further reduced cash outside OCF.
• Capital bridge: After IPO assumes midpoint pricing, preferred conversion, July financing and specified compensation adjustments. Before IPO, $201M of preferred stock sits outside equity, while accumulated losses of $(211)M deepen the deficit; it is not a borrowing deficit. July added $15.0M each from preferred financing and term-loan principal, taking pre-offering cash to $34.0M. Preferred conversion and related adjustments turn equity positive before offering proceeds.
• Fraud recovery: FY2025 included a $2.00M unrecoverable fraudulent-transfer loss; H1 2026 included a $0.389M additional recovery.

Governance and Control

• Voting shares carry ordinary voting rights; Blue Owl will exchange shares into economically equivalent non-voting stock to cap its voting ownership at 4.50%. Novo’s disclosed post-offering stake is 4.88%; no holder retains majority control.
• A staggered board, restricted director removal and limits on shareholder action make unsolicited control changes harder. Geoffrey McDonough became CEO in 2/2026.
• Enumerated options and warrants represent 4.29% of the diluted count, with $4.72M aggregate intrinsic value at midpoint. The capitalization bridge includes $2.80M of accelerated compensation expense. Additional conditional awards, the CEO’s ≈5% ownership-restoration arrangement and new equity reserves create further dilution.

Risk Assessment

• Reporting and survival: Going-concern doubt and material weaknesses in accounting oversight make funding completion and control remediation immediate priorities.
• Clinical leap: Biomarker improvements may not translate into walking benefit in previously untested peripheral artery disease patients, and regulators may require additional trials.
• Supply concentration: A sole ruvonoflast drug-substance supplier without full backup arrangements could interrupt the pivotal program.
• Commercial protection: Self-commercialization requires capabilities Rezera lacks, while competition, reimbursement and uncertain patent scope could limit returns.
• Strategic constraints: Conditional GSK negotiation rights could delay competing partnerships or acquisition proposals.
• Key personnel: Dependence on a small executive and specialist team, without key-person insurance, makes departures potentially disruptive.

What to Watch

• RELIEVE-PAD: Watch whether the planned trial starts, enrolls and ultimately improves walking distance; biomarker changes alone would not validate the investment thesis.
• Trabzanoflast: Phase 1 target engagement must progress into patient proof-of-concept; funding-driven deferral would leave the company concentrated in ruvonoflast.
• Funding execution: Compare actual spending and trial progress with the Q1 2029 runway claim; delays or expanded studies could force financing before the intended milestone.